Raymond James Financial Inc. Makes New $9.65 Million Investment in LivaNova PLC (NASDAQ:LIVN)

Raymond James Financial Inc. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 208,276 shares of the company’s stock, valued at approximately $9,645,000. Raymond James Financial Inc. owned approximately 0.38% of LivaNova at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares during the period. Geode Capital Management LLC raised its holdings in shares of LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after purchasing an additional 93,311 shares during the period. Paradice Investment Management LLC raised its holdings in shares of LivaNova by 15.3% in the 4th quarter. Paradice Investment Management LLC now owns 486,821 shares of the company’s stock valued at $22,545,000 after purchasing an additional 64,680 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of LivaNova by 286.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after purchasing an additional 153,611 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Stock Performance

Shares of NASDAQ:LIVN opened at $39.48 on Friday. The company’s 50 day moving average price is $45.31 and its two-hundred day moving average price is $48.75. LivaNova PLC has a 12-month low of $36.85 and a 12-month high of $64.48. The firm has a market cap of $2.15 billion, a PE ratio of 94.00 and a beta of 1.10. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.